Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Chaihu Anxin Capsule is a Traditional Chinese Medicine (TCM) botanical formulation developed by The First Hospital of Hebei Medical University for the treatment of mild to moderate depressive disorder. It is currently undergoing clinical evaluation in China to determine its efficacy and safety in patients experiencing a single episode of depression. The therapeutic approach involves investigating the drug's impact on the gut microbiome, suggesting a mechanism of action involving the gut-brain axis. The name 'Chaihu' refers to *Bupleurum*, a staple herb in TCM used for its purported ability to relieve emotional stagnation and regulate the liver-qi, which is traditionally linked to mood regulation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Chaihu Anxin Capsule.